Supplemental material
Research Articles
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study
Simina Ticaua Alnylam Pharmaceuticals, Cambridge, MA, USACorrespondence[email protected]
https://orcid.org/0000-0003-1096-9627View further author information
https://orcid.org/0000-0003-1096-9627View further author information, Emre Aldinca Alnylam Pharmaceuticals, Cambridge, MA, USAhttps://orcid.org/0000-0002-7237-4760View further author information
https://orcid.org/0000-0002-7237-4760View further author information, Michael Polydefkisb Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USAhttps://orcid.org/0000-0002-7584-7447View further author information
https://orcid.org/0000-0002-7584-7447View further author information, David Adamsc Neurology Department, AP-HP, CHU Bicêtre, Université Paris-Saclay, Paris-Saclay, Francehttps://orcid.org/0000-0002-8722-4108View further author information
https://orcid.org/0000-0002-8722-4108View further author information, , Mitsuharu Uedae Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japanhttps://orcid.org/0000-0002-6814-0582View further author information
https://orcid.org/0000-0002-6814-0582View further author information, , , Paul Nioia Alnylam Pharmaceuticals, Cambridge, MA, USAhttps://orcid.org/0000-0002-4804-8148View further author information
https://orcid.org/0000-0002-4804-8148View further author information & the Patisiran Global OLE Collaborators show all